BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30864675)

  • 1. Targeting excessive MYCN expression using MLN8237 and JQ1 impairs the growth of hepatoblastoma cells.
    Eberherr C; Beck A; Vokuhl C; Becker K; Häberle B; Von Schweinitz D; Kappler R
    Int J Oncol; 2019 May; 54(5):1853-1863. PubMed ID: 30864675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Killing of Human Neuroblastoma Cells by the Small Molecule JQ1 Occurs in a p53-Dependent Manner.
    Mazar J; Gordon C; Naga V; Westmoreland TJ
    Anticancer Agents Med Chem; 2020; 20(13):1613-1625. PubMed ID: 32329693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYCNOS functions as an antisense RNA regulating MYCN.
    Vadie N; Saayman S; Lenox A; Ackley A; Clemson M; Burdach J; Hart J; Vogt PK; Morris KV
    RNA Biol; 2015; 12(8):893-9. PubMed ID: 26156430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
    O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
    BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of
    Beck A; Trippel F; Wagner A; Joppien S; Felle M; Vokuhl C; Schwarzmayr T; Strom TM; von Schweinitz D; Längst G; Kappler R
    Clin Epigenetics; 2018; 10():27. PubMed ID: 29507645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYCN contributes to the malignant characteristics of erythroleukemia through EZH2-mediated epigenetic repression of p21.
    Liu L; Xu F; Chang CK; He Q; Wu LY; Zhang Z; Li X
    Cell Death Dis; 2017 Oct; 8(10):e3126. PubMed ID: 29022893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
    Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
    Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
    Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
    Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.
    Melaiu O; Mina M; Chierici M; Boldrini R; Jurman G; Romania P; D'Alicandro V; Benedetti MC; Castellano A; Liu T; Furlanello C; Locatelli F; Fruci D
    Clin Cancer Res; 2017 Aug; 23(15):4462-4472. PubMed ID: 28270499
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatoblastomas exhibit marked
    Rivas MP; Aguiar TFM; Maschietto M; Lemes RB; Caires-Júnior LC; Goulart E; Telles-Silva KA; Novak E; Cristofani LM; Odone V; Cypriano M; de Toledo SRC; Carraro DM; Escobar MQ; Lee H; Johnston M; da Costa CML; da Cunha IW; Tasic L; Pearson PL; Rosenberg C; Timchenko N; Krepischi ACV
    Tumour Biol; 2020 Dec; 42(12):1010428320977124. PubMed ID: 33256542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
    Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
    Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma.
    Clavería-Cabello A; Herranz JM; Latasa MU; Arechederra M; Uriarte I; Pineda-Lucena A; Prosper F; Berraondo P; Alonso C; Sangro B; García Marin JJ; Martinez-Chantar ML; Ciordia S; Corrales FJ; Francalanci P; Alaggio R; Zucman-Rossi J; Indersie E; Cairo S; Domingo-Sàbat M; Zanatto L; Sancho-Bru P; Armengol C; Berasain C; Fernandez-Barrena MG; Avila MA
    J Hepatol; 2023 Oct; 79(4):989-1005. PubMed ID: 37302584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells.
    Čančer M; Drews LF; Bengtsson J; Bolin S; Rosén G; Westermark B; Nelander S; Forsberg-Nilsson K; Uhrbom L; Weishaupt H; Swartling FJ
    Cell Death Dis; 2019 Nov; 10(12):881. PubMed ID: 31754113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GREB1 induced by Wnt signaling promotes development of hepatoblastoma by suppressing TGFβ signaling.
    Matsumoto S; Yamamichi T; Shinzawa K; Kasahara Y; Nojima S; Kodama T; Obika S; Takehara T; Morii E; Okuyama H; Kikuchi A
    Nat Commun; 2019 Aug; 10(1):3882. PubMed ID: 31462641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing of the Long Noncoding RNA MYCNOS1 Suppresses Activity of MYCN-Amplified Retinoblastoma Without RB1 Mutation.
    Saengwimol D; Chittavanich P; Laosillapacharoen N; Srimongkol A; Chaitankar V; Rojanaporn D; Aroonroch R; Suktitipat B; Saisawang C; Svasti S; Hongeng S; Kaewkhaw R
    Invest Ophthalmol Vis Sci; 2020 Dec; 61(14):8. PubMed ID: 33270844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
    Carrillo-Reixach J; Torrens L; Simon-Coma M; Royo L; Domingo-Sàbat M; Abril-Fornaguera J; Akers N; Sala M; Ragull S; Arnal M; Villalmanzo N; Cairo S; Villanueva A; Kappler R; Garrido M; Guerra L; Sábado C; Guillén G; Mallo M; Piñeyro D; Vázquez-Vitali M; Kuchuk O; Mateos ME; Ramírez G; Santamaría ML; Mozo Y; Soriano A; Grotzer M; Branchereau S; de Andoin NG; López-Ibor B; López-Almaraz R; Salinas JA; Torres B; Hernández F; Uriz JJ; Fabre M; Blanco J; Paris C; Bajčiová V; Laureys G; Masnou H; Clos A; Belendez C; Guettier C; Sumoy L; Planas R; Jordà M; Nonell L; Czauderna P; Morland B; Sia D; Losic B; Buendia MA; Sarrias MR; Llovet JM; Armengol C
    J Hepatol; 2020 Aug; 73(2):328-341. PubMed ID: 32240714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
    Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
    Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of
    Liu L; Cui Z; Zhang J; Wang J; Gu S; Ma J; Chen H; Hang L; Yang J; Shi Y
    Cancer Biother Radiopharm; 2020 Feb; 35(1):41-49. PubMed ID: 31916845
    [No Abstract]   [Full Text] [Related]  

  • 20. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
    Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
    Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.